FindTrial
Sign In

Durvalmab plus platinum-etoposide versus atezolizumab plus platinum-etoposide in extensive- stage small cell lung cancer: a systematic review.

Durvalmab plus platinum-etoposide versus atezolizumab plus platinum-etoposide in extensive- stage small cell lung cancer: a systematic review. - Durvalmab plus platinum-etoposide versus atezolizumab plus platinum-etoposide in extensive- stage small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000040194
Enrollment
Unknown
Registered
2020-04-20
Start date
2020-04-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extensive-stage (ES) small-cell lung cancer (SCLC) (ES-SCLC)

Interventions

None listed

Sponsors

Showa University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Phase 3 studies of duvalumab+platinu-etoposide or atezolizumab+platinum-etoposide Patiets with aged 18 years or more, histological or cytological confirmation of previously untreated advanced extensive disease small cell ling cancer, with performance status of 0 to 1

Exclusion criteria

Exclusion criteria: Case report Observational studies non-randomized controlled trials

Design outcomes

Primary

MeasureTime frame
Overall survival(OS)—

Secondary

MeasureTime frame
Progression free survival(PFS) Grade3-5 Any adverse events(G3-5AAEs) Grade3-5 neutropenia, anemia, thrombocytopenia—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University School of Medicine Department of Medicine, Division of Respiratory Medicine and Allergology,

koichi-a@med.showa-u.ac.jp+81-3-37848532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026